Upcoming Live Webinar - January 22, 2020
The drug development process has been demonstrated to be extremely costly, lengthy, and risky with significant rates of molecule attrition. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier on average.
To inform drug developers of the potential financial impacts of alternative drug development processes and outsourcing models, the Tufts CSDD conducted a study comparing traditional drug development programs to Quotient Sciences’ signature drug product manufacturing and clinical testing platform, referred to as Translational Pharmaceutics.
Translational Pharmaceutics is a unique platform which integrates formulation development, manufacturing and clinical testing and has been widely used by pharmaceutical and biotech companies to accelerate product development across the full development cycle.
Key applications of Translational Pharmaceutics include the transition of molecules from First in Human (FIH) to Proof of Concept (POC), and in the development and optimization of clinical formulations including modified release (MR) drug products and solubility enhanced dosage forms.
This webinar will summarize the key findings of the Tufts CSDD research on Translational Pharmaceutics, which includes mean time savings of >12 months and financial gains of >$100 million per drug approved.
Key Learning Objectives
- Discover the difference between Translational Pharmaceutics and traditional approaches to drug development.
- Realise the multi-million dollar benefits of Translational Pharmaceutics, as demonstrated in the Tufts CSDD study.
- Learn how much time and budget you could save on your drug development timeline.
- Uncover the findings of the Tufts CSDD study including a review of the methodology, results and key conclusions.
- Hear from real case studies which demonstrate how Translational Pharmaceutics can be utilised during drug development.